Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04974359 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04974359: Clinical Trial Phase 1 study, sponsored by H. Lundbeck A/S.
NCT04974359 is a Phase 1 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04974359, a Phase 1 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effect of Lu AG06466 on the body in participants with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental) assessments.
Primary Outcome
BOLD response was evaluated using Functional Magnetic Resonance Imaging (fMRI). During the evoked-pain test, each participant will undergo a block design scan, during which 3 cuff pressures ('light touch' = 30 millimeter of mercury \[mmHg\]; 'equal pressure' = 120 mmHg; 'equal pain' = 40 to 60/100 Numeric Rating Scale \[NRS\] units) will be applied to the left calf using the pressure cuff device in pseudo random order.
Interventions
- DRUG Placebo
- DRUG Lu AG06466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 1 |
Why NCT04974359 stopped before completion
NCT04974359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04974359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04974359 about?
NCT04974359 is a clinical study titled "A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia". The purpose of this study is to find out the effect of Lu AG06466 on the body in participants with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental) assessments.
What is the current status of trial NCT04974359?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-06-24. Estimated completion is 2022-01-26.
What interventions are being tested in trial NCT04974359?
The interventions under investigation include: Placebo (DRUG), Lu AG06466 (DRUG).
Who is sponsoring clinical trial NCT04974359?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04974359's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI